Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

類似資料

• Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
  著者:: Ascierto, Paolo Antonio, 等
  出版事項: (2020)
• Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
  著者:: Dummer, Reinhard, 等
  出版事項: (2014)
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
  著者:: Wolchok, J.D., 等
  出版事項: (2017)
• Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab With Alternative Therapies in the Management of Pretreated Patients With Unresectable Stage III or IV Melanoma
  著者:: Dequen, Pascale, 等
  出版事項: (2012)
• Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
  著者:: Tarhini, Ahmad, 等
  出版事項: (2018)